Markets:

Overview

News

Currencies

International

Treasuries

Mirum Pharmaceuticals, Inc. - common stock (NQ:MIRM)

78.87 -0.12 (-0.15%)

Streaming Delayed Price Updated: 10:52 AM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Mirum Pharmaceuticals, Inc. - common stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

The Latest Analyst Ratings for Mirum Pharmaceuticals ↗

June 15, 2023

Via Benzinga

Event-Free Survival Data from Mirum’s LIVMARLI Alagille Syndrome Program Published in Hepatology

June 14, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 09, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Present New LIVMARLI Data at the 2023 EASL Congress

June 07, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Analyst Expectations for Mirum Pharmaceuticals's Future ↗

May 22, 2023

Via Benzinga

Mirum Pharmaceuticals: Q1 Earnings Insights ↗

May 04, 2023

Via Benzinga

Analyst Expectations for Mirum Pharmaceuticals's Future ↗

April 06, 2023

Via Benzinga

Mirum Pharmaceuticals Earnings Perspective: Return On Capital Employed ↗

March 10, 2023

Via Benzinga

Week In Review: Betta Pharma Enters $392 Million Deal For C4 Therapeutics’ NSCLC Drug ↗

June 03, 2023

Hangzhou Betta Pharma acquired greater China rights for a novel non-small cell lung cancer drug from Boston’s C4 Therapeutics in a deal worth up to $392 million. Additionally, Lynk Pharma of Hangzhou...

Via Talk Markets

Data from Mirum’s LIVMARLI Studies Presented at ESPGHAN Annual Meeting

May 19, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Hepatology Communications Publishes Data from Mirum’s LIVMARLI in Primary Sclerosing Cholangitis

May 18, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Showcase LIVMARLI Data at ESPGHAN Annual Meeting

May 17, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Analyst Expectations for Mirum Pharmaceuticals's Future ↗

March 09, 2023

Via Benzinga

Mirum Pharmaceuticals Announces Enrollment Completion in Phase 2b EMBARK Biliary Atresia Study

May 11, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 10, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

May 04, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call on May 4, 2023

April 27, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Prices Upsized $275.0 Million Convertible Senior Notes Offering

April 13, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

American Airlines, Cutera, Mirum Pharmaceuticals And Other Big Stocks Moving Lower On Wednesday ↗

April 12, 2023

U.S. stocks traded mixed, with the Dow Jones gaining over 50 points on Wednesday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Why Panbela Therapeutics Shares Are Trading Higher By Around 25%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

April 12, 2023

Gainers TESSCO Technologies Incorporated (NASDAQ: TESS) shares jumped 86.8% to $8.78 as it agreed to be acquired by entities affiliated with Lee Equity Partners and Twin Point Capital for $9.00 in...

Via Benzinga

Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering

April 12, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Announces Preliminary Unaudited First Quarter 2023 Financial Results

April 12, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 10, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Industry Leader Tim Walbert Joins Mirum Pharmaceuticals’ Board of Directors

April 06, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Submits for European Approval of LIVMARLI in Progressive Familial Intrahepatic Cholestasis

April 05, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Announces Label Expansion for LIVMARLI in the United States to Include Infants Three Months of Age and Older

March 14, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Roku Has 26% Of Cash With SVB Financial, Deposit Recovery Uncertain — 27 Other Companies With Ties To Collapsed Bank ↗

March 11, 2023

The collapse of SVB Financial Group (NASDAQ: SIVB) could have a ripple effect on the technology and biotech industries, the two largest sectors that had deposits and financial relationships with the...

Via Benzinga

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 10, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update

March 08, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Earnings Scheduled For March 8, 2023 ↗

March 08, 2023

Companies Reporting Before The Bell • Daktronics (NASDAQ:DAKT) is expected to report quarterly earnings at $0.00 per share on revenue of $164.68 million.

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.